Loading…

Lipid-based nanoparticles for treatment of cancer

Investigators were continuously creating novel nanotechnologies to address unmet requirements throughout the administration of therapeutic medicines & imaging agents for cancer treatment & diagnostics, appropriately. LNPs(Lipid nanoparticles) are legitimate particulates (approx. 100 nm in si...

Full description

Saved in:
Bibliographic Details
Published in:Heliyon 2022-05, Vol.8 (5), p.e09403, Article e09403
Main Authors: Sheoran, Sumit, Arora, Swati, Samsonraj, R., Govindaiah, Pilli, vuree, Sugunakar
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c533t-afae5a9b2a5d368c3e9ca50935c80b19d41e2399094d43f4d42a7ec9028f18383
cites cdi_FETCH-LOGICAL-c533t-afae5a9b2a5d368c3e9ca50935c80b19d41e2399094d43f4d42a7ec9028f18383
container_end_page
container_issue 5
container_start_page e09403
container_title Heliyon
container_volume 8
creator Sheoran, Sumit
Arora, Swati
Samsonraj, R.
Govindaiah, Pilli
vuree, Sugunakar
description Investigators were continuously creating novel nanotechnologies to address unmet requirements throughout the administration of therapeutic medicines & imaging agents for cancer treatment & diagnostics, appropriately. LNPs(Lipid nanoparticles) are legitimate particulates (approx. 100 nm in size) gathered from various lipid as well as other biochemical compounds which overall functionality to resolve biological barriers (biobarriers), allowing LNPs to selectively collect somewhere outside of disease-target cells again for responsive therapeutics. Most pharmaceutically important compounds were insoluble throughout water solutions, were chemical & physiologically unstable, or have toxicities. Among the most potential drug carrier for bioactive organic compounds is LBNPs (Lipid based nanoparticles) technologies. Its present use in chemotherapy have transformed treatment for cancer by increasing the antitumor effect of a number of chemotherapeutics. Because they may be created using naturally occurring sources, LBNPs have great temporal and thermal stability, maximum load potential, simplicity of preparations, cheap manufacturing costs, & big manufacturing output. Furthermore, combining chemotherapeutic drugs with LNPs reduces active therapeutic dosage and toxicities, lowers treatment resistance, & raises drug concentration in tumour cells while reducing concentrations in normal tissue. LBNPs were widely studied in cancer treatment, both in vitro and in vivo, with encouraging outcomes in certain clinical trials. This study provides an overview of the many types of LBNPs which have been created in latest years and their applications and contributions in different types of cancers. Lipoid based nanoparticles; Tumour; Clinical trials; Liposomes; Solid lipid nanoparticles.
doi_str_mv 10.1016/j.heliyon.2022.e09403
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_3a25d775a3cd4a5b94c15d5aa5ea6a52</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2405844022006910</els_id><doaj_id>oai_doaj_org_article_3a25d775a3cd4a5b94c15d5aa5ea6a52</doaj_id><sourcerecordid>2674009174</sourcerecordid><originalsourceid>FETCH-LOGICAL-c533t-afae5a9b2a5d368c3e9ca50935c80b19d41e2399094d43f4d42a7ec9028f18383</originalsourceid><addsrcrecordid>eNqFkU1v1DAQhi0EolXpTwDlyCXL-DPxBYQqPiqtxAXO1sSetF5l48XOVuq_xyVL1Z642Jb9zjOv52XsLYcNB24-7Da3NMX7NG8ECLEhsArkC3YuFOi2VwpePjmfsctSdgDAdW9sJ1-zM6mNkZ2054xv4yGGdsBCoZlxTgfMS_QTlWZMuVky4bKneWnS2HicPeU37NWIU6HL037Bfn398vPqe7v98e366vO29VrKpcURSaMdBOogTe8lWY8arNS-h4HboDgJaW21HpQc6yKwI29B9CPvZS8v2PXKDQl37pDjHvO9Sxjd34uUb9zJqpModOg6jdIHhXqwynMdNKImNKhFZX1cWYfjsKfg64cyTs-gz1_meOtu0p2z3AAoUwHvT4Ccfh-pLG4fi6dpwpnSsThhOgVgeaeqVK9Sn1MpmcbHNhzcQ3pu507puYf03JperXv31ONj1b-squDTKqA69btI2RUfqUYSYia_1LHE_7T4A2c9rj4</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2674009174</pqid></control><display><type>article</type><title>Lipid-based nanoparticles for treatment of cancer</title><source>ScienceDirect Journals</source><source>PubMed Central</source><creator>Sheoran, Sumit ; Arora, Swati ; Samsonraj, R. ; Govindaiah, Pilli ; vuree, Sugunakar</creator><creatorcontrib>Sheoran, Sumit ; Arora, Swati ; Samsonraj, R. ; Govindaiah, Pilli ; vuree, Sugunakar</creatorcontrib><description>Investigators were continuously creating novel nanotechnologies to address unmet requirements throughout the administration of therapeutic medicines &amp; imaging agents for cancer treatment &amp; diagnostics, appropriately. LNPs(Lipid nanoparticles) are legitimate particulates (approx. 100 nm in size) gathered from various lipid as well as other biochemical compounds which overall functionality to resolve biological barriers (biobarriers), allowing LNPs to selectively collect somewhere outside of disease-target cells again for responsive therapeutics. Most pharmaceutically important compounds were insoluble throughout water solutions, were chemical &amp; physiologically unstable, or have toxicities. Among the most potential drug carrier for bioactive organic compounds is LBNPs (Lipid based nanoparticles) technologies. Its present use in chemotherapy have transformed treatment for cancer by increasing the antitumor effect of a number of chemotherapeutics. Because they may be created using naturally occurring sources, LBNPs have great temporal and thermal stability, maximum load potential, simplicity of preparations, cheap manufacturing costs, &amp; big manufacturing output. Furthermore, combining chemotherapeutic drugs with LNPs reduces active therapeutic dosage and toxicities, lowers treatment resistance, &amp; raises drug concentration in tumour cells while reducing concentrations in normal tissue. LBNPs were widely studied in cancer treatment, both in vitro and in vivo, with encouraging outcomes in certain clinical trials. This study provides an overview of the many types of LBNPs which have been created in latest years and their applications and contributions in different types of cancers. Lipoid based nanoparticles; Tumour; Clinical trials; Liposomes; Solid lipid nanoparticles.</description><identifier>ISSN: 2405-8440</identifier><identifier>EISSN: 2405-8440</identifier><identifier>DOI: 10.1016/j.heliyon.2022.e09403</identifier><identifier>PMID: 35663739</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Clinical trials ; Lipid based Nanopartcles ; Liposomes ; Review ; Solid lipid nanoparticles ; Tumour</subject><ispartof>Heliyon, 2022-05, Vol.8 (5), p.e09403, Article e09403</ispartof><rights>2022</rights><rights>2022 Published by Elsevier Ltd.</rights><rights>2022 Published by Elsevier Ltd. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c533t-afae5a9b2a5d368c3e9ca50935c80b19d41e2399094d43f4d42a7ec9028f18383</citedby><cites>FETCH-LOGICAL-c533t-afae5a9b2a5d368c3e9ca50935c80b19d41e2399094d43f4d42a7ec9028f18383</cites><orcidid>0000-0002-2519-8506 ; 0000-0002-3262-434X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160046/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S2405844022006910$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3549,27924,27925,45780,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35663739$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sheoran, Sumit</creatorcontrib><creatorcontrib>Arora, Swati</creatorcontrib><creatorcontrib>Samsonraj, R.</creatorcontrib><creatorcontrib>Govindaiah, Pilli</creatorcontrib><creatorcontrib>vuree, Sugunakar</creatorcontrib><title>Lipid-based nanoparticles for treatment of cancer</title><title>Heliyon</title><addtitle>Heliyon</addtitle><description>Investigators were continuously creating novel nanotechnologies to address unmet requirements throughout the administration of therapeutic medicines &amp; imaging agents for cancer treatment &amp; diagnostics, appropriately. LNPs(Lipid nanoparticles) are legitimate particulates (approx. 100 nm in size) gathered from various lipid as well as other biochemical compounds which overall functionality to resolve biological barriers (biobarriers), allowing LNPs to selectively collect somewhere outside of disease-target cells again for responsive therapeutics. Most pharmaceutically important compounds were insoluble throughout water solutions, were chemical &amp; physiologically unstable, or have toxicities. Among the most potential drug carrier for bioactive organic compounds is LBNPs (Lipid based nanoparticles) technologies. Its present use in chemotherapy have transformed treatment for cancer by increasing the antitumor effect of a number of chemotherapeutics. Because they may be created using naturally occurring sources, LBNPs have great temporal and thermal stability, maximum load potential, simplicity of preparations, cheap manufacturing costs, &amp; big manufacturing output. Furthermore, combining chemotherapeutic drugs with LNPs reduces active therapeutic dosage and toxicities, lowers treatment resistance, &amp; raises drug concentration in tumour cells while reducing concentrations in normal tissue. LBNPs were widely studied in cancer treatment, both in vitro and in vivo, with encouraging outcomes in certain clinical trials. This study provides an overview of the many types of LBNPs which have been created in latest years and their applications and contributions in different types of cancers. Lipoid based nanoparticles; Tumour; Clinical trials; Liposomes; Solid lipid nanoparticles.</description><subject>Clinical trials</subject><subject>Lipid based Nanopartcles</subject><subject>Liposomes</subject><subject>Review</subject><subject>Solid lipid nanoparticles</subject><subject>Tumour</subject><issn>2405-8440</issn><issn>2405-8440</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNqFkU1v1DAQhi0EolXpTwDlyCXL-DPxBYQqPiqtxAXO1sSetF5l48XOVuq_xyVL1Z642Jb9zjOv52XsLYcNB24-7Da3NMX7NG8ECLEhsArkC3YuFOi2VwpePjmfsctSdgDAdW9sJ1-zM6mNkZ2054xv4yGGdsBCoZlxTgfMS_QTlWZMuVky4bKneWnS2HicPeU37NWIU6HL037Bfn398vPqe7v98e366vO29VrKpcURSaMdBOogTe8lWY8arNS-h4HboDgJaW21HpQc6yKwI29B9CPvZS8v2PXKDQl37pDjHvO9Sxjd34uUb9zJqpModOg6jdIHhXqwynMdNKImNKhFZX1cWYfjsKfg64cyTs-gz1_meOtu0p2z3AAoUwHvT4Ccfh-pLG4fi6dpwpnSsThhOgVgeaeqVK9Sn1MpmcbHNhzcQ3pu507puYf03JperXv31ONj1b-squDTKqA69btI2RUfqUYSYia_1LHE_7T4A2c9rj4</recordid><startdate>20220501</startdate><enddate>20220501</enddate><creator>Sheoran, Sumit</creator><creator>Arora, Swati</creator><creator>Samsonraj, R.</creator><creator>Govindaiah, Pilli</creator><creator>vuree, Sugunakar</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-2519-8506</orcidid><orcidid>https://orcid.org/0000-0002-3262-434X</orcidid></search><sort><creationdate>20220501</creationdate><title>Lipid-based nanoparticles for treatment of cancer</title><author>Sheoran, Sumit ; Arora, Swati ; Samsonraj, R. ; Govindaiah, Pilli ; vuree, Sugunakar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c533t-afae5a9b2a5d368c3e9ca50935c80b19d41e2399094d43f4d42a7ec9028f18383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Clinical trials</topic><topic>Lipid based Nanopartcles</topic><topic>Liposomes</topic><topic>Review</topic><topic>Solid lipid nanoparticles</topic><topic>Tumour</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sheoran, Sumit</creatorcontrib><creatorcontrib>Arora, Swati</creatorcontrib><creatorcontrib>Samsonraj, R.</creatorcontrib><creatorcontrib>Govindaiah, Pilli</creatorcontrib><creatorcontrib>vuree, Sugunakar</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Heliyon</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sheoran, Sumit</au><au>Arora, Swati</au><au>Samsonraj, R.</au><au>Govindaiah, Pilli</au><au>vuree, Sugunakar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lipid-based nanoparticles for treatment of cancer</atitle><jtitle>Heliyon</jtitle><addtitle>Heliyon</addtitle><date>2022-05-01</date><risdate>2022</risdate><volume>8</volume><issue>5</issue><spage>e09403</spage><pages>e09403-</pages><artnum>e09403</artnum><issn>2405-8440</issn><eissn>2405-8440</eissn><abstract>Investigators were continuously creating novel nanotechnologies to address unmet requirements throughout the administration of therapeutic medicines &amp; imaging agents for cancer treatment &amp; diagnostics, appropriately. LNPs(Lipid nanoparticles) are legitimate particulates (approx. 100 nm in size) gathered from various lipid as well as other biochemical compounds which overall functionality to resolve biological barriers (biobarriers), allowing LNPs to selectively collect somewhere outside of disease-target cells again for responsive therapeutics. Most pharmaceutically important compounds were insoluble throughout water solutions, were chemical &amp; physiologically unstable, or have toxicities. Among the most potential drug carrier for bioactive organic compounds is LBNPs (Lipid based nanoparticles) technologies. Its present use in chemotherapy have transformed treatment for cancer by increasing the antitumor effect of a number of chemotherapeutics. Because they may be created using naturally occurring sources, LBNPs have great temporal and thermal stability, maximum load potential, simplicity of preparations, cheap manufacturing costs, &amp; big manufacturing output. Furthermore, combining chemotherapeutic drugs with LNPs reduces active therapeutic dosage and toxicities, lowers treatment resistance, &amp; raises drug concentration in tumour cells while reducing concentrations in normal tissue. LBNPs were widely studied in cancer treatment, both in vitro and in vivo, with encouraging outcomes in certain clinical trials. This study provides an overview of the many types of LBNPs which have been created in latest years and their applications and contributions in different types of cancers. Lipoid based nanoparticles; Tumour; Clinical trials; Liposomes; Solid lipid nanoparticles.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>35663739</pmid><doi>10.1016/j.heliyon.2022.e09403</doi><orcidid>https://orcid.org/0000-0002-2519-8506</orcidid><orcidid>https://orcid.org/0000-0002-3262-434X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2405-8440
ispartof Heliyon, 2022-05, Vol.8 (5), p.e09403, Article e09403
issn 2405-8440
2405-8440
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_3a25d775a3cd4a5b94c15d5aa5ea6a52
source ScienceDirect Journals; PubMed Central
subjects Clinical trials
Lipid based Nanopartcles
Liposomes
Review
Solid lipid nanoparticles
Tumour
title Lipid-based nanoparticles for treatment of cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T08%3A26%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lipid-based%20nanoparticles%20for%20treatment%20of%20cancer&rft.jtitle=Heliyon&rft.au=Sheoran,%20Sumit&rft.date=2022-05-01&rft.volume=8&rft.issue=5&rft.spage=e09403&rft.pages=e09403-&rft.artnum=e09403&rft.issn=2405-8440&rft.eissn=2405-8440&rft_id=info:doi/10.1016/j.heliyon.2022.e09403&rft_dat=%3Cproquest_doaj_%3E2674009174%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c533t-afae5a9b2a5d368c3e9ca50935c80b19d41e2399094d43f4d42a7ec9028f18383%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2674009174&rft_id=info:pmid/35663739&rfr_iscdi=true